{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["5(9)"],"submitter":["Simoni-Nieves A"],"pubmed_abstract":["Activating EGFR (epidermal growth factor receptor) mutations can be inhibited by specific tyrosine kinase inhibitors (TKIs), which have changed the landscape of lung cancer therapy. However, due to secondary mutations and bypass receptors, such as AXL (AXL receptor tyrosine kinase), drug resistance eventually emerges in most patients treated with the first-, second-, or third-generation TKIs (e.g., osimertinib). To inhibit AXL and resistance to osimertinib, we compare two anti-AXL drugs, an antibody (mAb654) and a TKI (bemcentinib). While no pair of osimertinib and an anti-AXL drug is able to prevent relapses, triplets combining osimertinib, cetuximab (an anti-EGFR antibody), and either anti-AXL drug are initially effective. However, longer monitoring uncovers superiority of the mAb654-con"],"journal":["Cell reports. Medicine"],"pagination":["101703"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11528239"],"repository":["biostudies-literature"],"pubmed_title":["A bispecific antibody targeting EGFR and AXL delays resistance to osimertinib."],"pmcid":["PMC11528239"],"pubmed_authors":["Marrocco I","Tsutsumi Y","Yarden Y","Haga Y","Giri S","Salame TM","Romaniello D","Van Daele M","Love D","Lindzen M","Oren R","Chatterjee R","Simoni-Nieves A","Gupta N","Zerbib M","Lauriola M","Selvadurai BR"],"additional_accession":[]},"is_claimable":false,"name":"A bispecific antibody targeting EGFR and AXL delays resistance to osimertinib.","description":"Activating EGFR (epidermal growth factor receptor) mutations can be inhibited by specific tyrosine kinase inhibitors (TKIs), which have changed the landscape of lung cancer therapy. However, due to secondary mutations and bypass receptors, such as AXL (AXL receptor tyrosine kinase), drug resistance eventually emerges in most patients treated with the first-, second-, or third-generation TKIs (e.g., osimertinib). To inhibit AXL and resistance to osimertinib, we compare two anti-AXL drugs, an antibody (mAb654) and a TKI (bemcentinib). While no pair of osimertinib and an anti-AXL drug is able to prevent relapses, triplets combining osimertinib, cetuximab (an anti-EGFR antibody), and either anti-AXL drug are initially effective. However, longer monitoring uncovers superiority of the mAb654-con","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Sep","modification":"2026-07-16T03:05:08.657Z","creation":"2025-04-04T00:29:49.981Z"},"accession":"S-EPMC11528239","cross_references":{"pubmed":["39216477"],"doi":["10.1016/j.xcrm.2024.101703"]}}